Monkeypox Treatment Market: By Treatment Type (Prophylactic, Vaccines, Therapeutics, Tecovirimat, Brincidofovir, and Cidofovir), By Route of Administration (Oral and Injectable) By Application (Medical Imaging, Nuclear Medicine, Radioprotection, Oil Exploration, Process Industry, Life Sciences, and Others) By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies, and Others), and Geography 

Purchase Option

$ 4400
$ 6600
$ 8900

Monkeypox Treatment Market size was valued at USD 86.4 million in 2023 which is expected to grow at a CAGR of 18.2% from 2024-2030. Two outbursts of an ailment similar to pox in gatherings of monkeys kept for research helped in the discovery of monkeypox in 1958. The monkeypox virus is the cause of monkeypox disease. Monkeypox is a type of Zoonotic disease, which is transferred from animals to humans. The virus that sources monkeypox and smallpox both come from the same virus family. However, when compared to smallpox, monkeypox is less severe. The symptoms of monkeypox are the same as smallpox but they are mild and usually non-lethal.

The rising prevalence of monkeypox caused by the monkeypox virus can lead to the monkeypox treatment market growth. Moreover, the increase in numerous dermatology diseases for example eczema and chronic disorders which consequences in weak immunity with higher probabilities of getting infested with the monkeypox virus, and growth in research and development for monkeypox treatment because of increasing demand for the cure are some primary factors that can boost the global monkeypox treatment market. Apart from these, the coronavirus pandemic has reduced the immunity of most people who are easily prone to monkeypox which can also accelerate the market in the future. However, some factors such as the rising side effects associated with drugs such as dysphoria, mild upset stomach, decreased concentration, and dry mouth can restrain the growth of the market. The absence of awareness about the monkeypox disease and lack of information about helpful treatment, as well as the sluggish sanction of certain beneficial treatments for monkeypox can hinder the market growth. Rising demand for monkeypox treatment and an increase in research and development activities for specific monkeypox treatments can create an opportunity for the global monkeypox treatment market growth.

Monkeypox Treatment Market Key Developments:
  • In July 2022, the U.S. Department of Health and Human Services (HHS) signed an agreement with Bavarian Nordic for 2.5 million doses of the Jynneos vaccine for the fast accessibility of the vaccines in the U.S.
  • In July 2022, Bavarian Nordic received European approval for extending the vaccine label including monkeypox.

Monkeypox Treatment Market Summary

Study Period

2024-2030

Base Year

2023

CAGR

18.2%

Largest Market

North America

Fastest Growing Market

Europe
Monkeypox Treatment Market Dynamics

One of the major reasons for the global monkeypox treatment market growth is the increase in investments in monkeypox drugs and vaccines. There are numerous shares of vaccine producers, antiviral drug makers, and protective apparatus producers which are in demand as stockholders are playing on an approach that proved to be pretty beneficial during the COVID-19 pandemic. Till now, pharmaceutical firms and biotechnological companies are among the growth stocks that are in focus with the medical device supplier. All these factors are expected to propel the growth of the market in the forecast period.

Monkeypox Treatment Market Segmentation

By Treatment Type
  • Prophylactic
  • Vaccines
  • Therapeutics
  • Tecovirimat
  • Brincidofovir
  • Cidofovir
By Route Administration
  • Oral
  • Injectable)
By Application
  • Medical Imaging
  • Nuclear Medicine
  • Radioprotection
  • Oil Exploration
  • Process Industry
  • Life Sciences
  • Others
By Distribution Channel
  • Retail Pharmacies
  • Hospital Pharmacies
  • Online Pharmacies
  • Others

Frequently Asked Questions

The monkeypox treatment market is projected to expand at a 18.2% CACR during the forecast period

Bavarian Nordic, SIGA Technologies, Chimerix, BioFactura, Inc., Tonix Pharmaceuticals Holding Corp., SymBio Pharmaceuticals Limited, Gilead Sciences, Inc., Aspen Holdings, Emcure Pharmaceuticals, Baxter, Grifols S.A., EMERGENT, Hetero, Olon S.p.A., Piramal Enterprises Ltd  

North America is the fastest-growing region for monkeypox treatment market

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
1. Executive Summary
2. Global Monkeypox Market Introduction
2.1. Global Monkeypox Market Taxonomy
2.2. Global Monkeypox Market Definitions
2.2.1. By Treatment Type
2.2.2. By Route of Administration
2.2.3. By Distribution Channel
2.2.4. By Route of Administration
3. Global Monkeypox Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Monkeypox Market Dynamic Factors - Impact Analysis
3.6. Global Monkeypox Market Competition Landscape
3.7. Epidemiology
4. Global Monkeypox Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030
4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Opportunity Analysis
5. Global Monkeypox Market, By Treatment Type, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
5.1. Prophylactic
5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. Vaccines
5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
5.3. Therapeutics
5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.3. Market Opportunity Analysis
5.4. Tecovirimat
5.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.4.3. Market Opportunity Analysis
5.5. Brincidofovir
5.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.5.3. Market Opportunity Analysis
5.6. Cidofovir
5.6.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
5.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.6.3. Market Opportunity Analysis
6. Global Monkeypox Market, By Route of Administration, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
6.1. Oral
6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Injectable
6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
7. Global Monkeypox Market, By Distribution Channel, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
7.1. Retail Pharmacies
7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Hospital Pharmacies
7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Online Pharmacies
7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
7.4. Others
7.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.4.3. Market Opportunity Analysis
8. Global Monkeypox Market Forecast, By Region, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
8.1. North America
8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.1.3. Market Opportunity Analysis
8.2. Europe
8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.2.3. Market Opportunity Analysis
8.3. Asia-Pacific
8.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.3.3. Market Opportunity Analysis
8.4. Latin America
8.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.4.3. Market Opportunity Analysis
8.5. Middle East and Africa
8.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.5.3. Market Opportunity Analysis
8.6. Global Monkeypox Market - Opportunity Analysis Index, By Treatment Type, By Route of Administration, By Distribution Channel, and Region, 2024 - 2030
9. North America Monkeypox Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
9.1. Treatment Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.1.1. Prophylactic
9.1.2. Vaccines
9.1.3. Therapeutics
9.1.4. Tecovirimat
9.1.5. Brincidofovir
9.1.6. Cidofovir
9.2. Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.2.1. Oral
9.2.2. Injectable
9.3. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.3.1. Retail Pharmacies
9.3.2. Hospital Pharmacies
9.3.3. Online Pharmacies
9.3.4. Others
9.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
9.4.1. USA
9.4.2. Canada
9.5. North America Monkeypox Market - Opportunity Analysis Index, By Treatment Type, By Route of Administration, By Distribution Channel, and Country, 2024 - 2030
9.6. North America Monkeypox Market Dynamics Trends
10. Europe Monkeypox Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
10.1. Treatment Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.1.1. Prophylactic
10.1.2. Vaccines
10.1.3. Therapeutics
10.1.4. Tecovirimat
10.1.5. Brincidofovir
10.1.6. Cidofovir
10.2. Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.2.1. Oral
10.2.2. Injectable
10.3. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.3.1. Retail Pharmacies
10.3.2. Hospital Pharmacies
10.3.3. Online Pharmacies
10.3.4. Others
10.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
10.4.1. Germany
10.4.2. UK
10.4.3. France
10.4.4. Spain
10.4.5. Italy
10.4.6. Rest of Europe
10.5. Europe Monkeypox Market - Opportunity Analysis Index, By Treatment Type, By Route of Administration, By Distribution Channel, and Country, 2024 - 2030
10.6. Europe Monkeypox Market Dynamics Trends
11. Asia-Pacific Monkeypox Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
11.1. Treatment Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.1. Prophylactic
11.1.2. Vaccines
11.1.3. Therapeutics
11.1.4. Tecovirimat
11.1.5. Brincidofovir
11.1.6. Cidofovir
11.2. Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.2.1. Oral
11.2.2. Injectable
11.3. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.3.1. Retail Pharmacies
11.3.2. Hospital Pharmacies
11.3.3. Online Pharmacies
11.3.4. Others
11.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
11.4.1. China
11.4.2. India
11.4.3. Japan
11.4.4. ASEAN
11.4.5. Australia & New Zealand
11.4.6. Rest of Asia-Pacific
11.5. Asia-Pacific Monkeypox Market - Opportunity Analysis Index, By Treatment Type, By Route of Administration By Distribution Channel, and Country, 2024 - 2030
11.6. Asia-Pacific Monkeypox Market Dynamics Trends
12. Latin America Monkeypox Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
12.1. Treatment Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.1. Prophylactic
12.1.2. Vaccines
12.1.3. Therapeutics
12.1.4. Tecovirimat
12.1.5. Brincidofovir
12.1.6. Cidofovir
12.2. Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.2.1. Oral
12.2.2. Injectable
12.3. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.3.1. Retail Pharmacies
12.3.2. Hospital Pharmacies
12.3.3. Online Pharmacies
12.3.4. Others
12.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
12.5. Latin America Monkeypox Market - Opportunity Analysis Index, By Treatment Type, By Route of Administration, By Distribution Channel, and Country, 2024 - 2030
12.6. Latin America Monkeypox Market Dynamics Trends
13. Middle East and Africa Monkeypox Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
13.1. Treatment Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.1.1. Prophylactic
13.1.2. Vaccines
13.1.3. Therapeutics
13.1.4. Tecovirimat
13.1.5. Brincidofovir
13.1.6. Cidofovir
13.2. Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.2.1. Oral
13.2.2. Injectable
13.3. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.3.1. Retail Pharmacies
13.3.2. Hospital Pharmacies
13.3.3. Online Pharmacies
13.3.4. Others
13.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
13.4.1. Gulf Cooperation Council (GCC) Countries
13.4.2. South Africa
13.4.3. Rest of MEA
13.5. MEA Monkeypox Market- Opportunity Analysis Index, By Treatment Type, By Route of Administration, By Distribution Channel, and Country, 2024 - 2030
13.6. MEA Monkeypox Market Dynamics Trends
14. Competition Landscape
14.1. Strategic Dashboard of Top Market Players
14.2. Company Profiles (Introduction, Financial Analysis, Key Treatment Types, Key Developments, Strategies, and SWOT Analysis)
14.2.1. Bavarian Nordic (Denmark)
14.2.2. SIGA Technologies (U.S.)
14.2.3. Chimerix (U.S.)
14.2.4. BioFactura, Inc. (U.S.)
14.2.5. Tonix Pharmaceuticals Holding Corp. (U.S.)
14.2.6. SymBio Pharmaceuticals Limited (Japan)
14.2.7. Gilead Sciences, Inc. (U.S.)
14.2.8. Aspen Holdings (South Africa)
14.2.9. Emcure Pharmaceuticals (India)
14.2.10. Baxter (U.S.)
14.2.11. Grifols S.A. (Spain)
14.2.12. EMERGENT (U.S.)
14.2.13. Hetero (India)
14.2.14. Olon S.p.A. (Italy)
14.2.15. Piramal Enterprises Ltd. (India)
15. Research Methodology
16. Key Assumptions and Acronyms
  • Bavarian Nordic
  • SIGA Technologies
  • Chimerix
  • BioFactura, Inc.
  • Tonix Pharmaceuticals Holding Corp.
  • SymBio Pharmaceuticals Limited
  • Gilead Sciences, Inc.
  • Aspen Holdings
  • Emcure Pharmaceuticals
  • Baxter
  • Grifols S.A.
  • EMERGENT
  • Hetero
  • Olon S.p.A.
  • Piramal Enterprises Ltd

Adjacent Markets